RSV Diagnostics Comprehensive Study by Type (Kits and Assays, Instruments, Other Products), Application (Detection of RSV, Prevention RSV), End-User (Hospitals and Clinics, Clinical Laboratories, Home Care), Patient (Infants, Older Adults), RSV type (Type A, Type B), Method (Rapid antigen detection tests (RADTs), Direct fluorescent antibody (DFA), Polymerase chain reaction (PCR) testing, Molecular Diagnostics, Enzyme-Linked Immunosorbent Assays, Immunofluorescence Assays, Chromatographic Immunoassays, Optical Immunoassays, Other Methods) Players and Region - Global Market Outlook to 2024

RSV Diagnostics Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
RSV Diagnostics Market Definition
RSV stands for Respiratory Synctical Virus It is very commonly found in paediatrics very contagious, virus that infects the respiratory tract. Even a certain low level of infection can lead to serious life-threatening problems such as pneumonia or bronchiolitis. Therefore the early diagnosis is essential to prevent the disease and save lives. Different devices like kits, analyzers are available in the market which used to detect and diagnosed this disease.

The market study is broken down by Type (Kits and Assays, Instruments and Other Products), by Application (Detection of RSV and Prevention RSV) and major geographies with country level splits.

There is strong competition between leading firms as this product is more helpful in paediatrics more than other age group consumers. Paediatric care is one of the sensitive topics which require all attention. Therefore leading firms launching easy to use point care devices and user-friendly devices. The competition is high as the new products are launching and also there is one threat of launching vaccines for RSV treatment reason why companies wanted to make a profit in present as in future if the introduction of vaccines then it will difficult to earn good business.

Abbott (United States), Becton, Dickinson and Company (United States), Roche (Switzerland), Danaher Corporation (Cepheid Inc) (United States), Thermo Fisher Scientific (United States), Sekisui diagnostics (United States), Vela Diagnostic (Singapore), Biomérieux (France), Luminex (United States), Biocartis (Belgium) and Hologic (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global RSV Diagnostics market by Type, Application and Region.

On the basis of geography, the market of RSV Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Hospitals and Clinics will boost the RSV Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Patient, the sub-segment i.e. Infants will boost the RSV Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by RSV type, the sub-segment i.e. Type A will boost the RSV Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Method, the sub-segment i.e. Rapid antigen detection tests (RADTs) will boost the RSV Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 12th February 2020 BD and Babson Diagnostics Announce Strategic Partnership Agreement to Enable Small-Volume Blood Collection for Diagnostic Testing in Retail Settings BD (Becton, Dickinson and Company), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood-testing company, today announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies. The partnership reflects emerging health care trends toward faster, less expensive laboratory testing in customer-friendly health care settings with more convenient hours and locations, as well as rapid growth in the diagnostic testing market.
On 12th November 2019, BD Submits Pre-Market Approval Supplement to FDA for BD Onclarity HPV Test with Extended Genotyping Capabilities BD (Becton, Dickinson and Company) a leading global medical technology company, announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity HPV Assay. The FDA-approved BD Onclarity HPV Assay detects 14 types of high-risk human papillomavirus (HPV) from specimens collected for cervical cancer screening in the BD SurePath Collection Vial.
The US FDA prescribes the following guidelines regarding assist sponsors in the clinical development of drugs for the treatment and prevention of disease caused by respiratory syncytial virus (RSV) infection. Guidance is intended to serve as a focus for continued discussions among the Division of Antiviral Products (DAVP), pharmaceutical sponsors, the academic community, and the public. This guidance focuses primarily on the development of drugs with the antiviral mechanism for RSV-related illness in infants and young children (e.g., bronchiolitis) but also briefly discusses development for other populations. The sections of this guidance that discuss nonclinical development are intended to guide drug development for both prophylaxis and treatment. It also regulates medical devices for diagnosis of RSV disease.

Market Trend
  • Medication Called Palivizumab Prevent RSV Infections And Protect

Market Drivers
  • Increasing Respiratory Syncytial Virus
  • High-Risk Babies From Serious Complications Of RSV Infection Can Cause Fatal
  • Increasing Demand For Point Care Diagnosis

Opportunities
  • Most Common Disease Found In Pediatrics

Restraints
  • Test Is only Accurate Till 80% To 90%
  • High cost associated with the product

Challenges
  • On-Going Study on RSV vaccines


Key Target Audience
Manufacturers and vendors of respiratory syncytial virus diagnostic, Research associations, Research and consulting firms, Distributors of respiratory syncytial virus diagnostic products, Contract manufacturers of diagnostic products, Healthcare institutions and Research institutes

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Kits and Assays
  • Instruments
  • Other Products
By Application
  • Detection of RSV
  • Prevention RSV
By End-User
  • Hospitals and Clinics
  • Clinical Laboratories
  • Home Care

By Patient
  • Infants
  • Older Adults

By RSV type
  • Type A
  • Type B

By Method
  • Rapid antigen detection tests (RADTs)
  • Direct fluorescent antibody (DFA)
  • Polymerase chain reaction (PCR) testing
  • Molecular Diagnostics
  • Enzyme-Linked Immunosorbent Assays
  • Immunofluorescence Assays
  • Chromatographic Immunoassays
  • Optical Immunoassays
  • Other Methods

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Respiratory Syncytial Virus
      • 3.2.2. High-Risk Babies From Serious Complications Of RSV Infection Can Cause Fatal
      • 3.2.3. Increasing Demand For Point Care Diagnosis
    • 3.3. Market Challenges
      • 3.3.1. On-Going Study on RSV vaccines
    • 3.4. Market Trends
      • 3.4.1. Medication Called Palivizumab Prevent RSV Infections And Protect
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global RSV Diagnostics, by Type, Application, End-User, Patient, RSV type, Method and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global RSV Diagnostics (Value)
      • 5.2.1. Global RSV Diagnostics by: Type (Value)
        • 5.2.1.1. Kits and Assays
        • 5.2.1.2. Instruments
        • 5.2.1.3. Other Products
      • 5.2.2. Global RSV Diagnostics by: Application (Value)
        • 5.2.2.1. Detection of RSV
        • 5.2.2.2. Prevention RSV
      • 5.2.3. Global RSV Diagnostics by: End-User (Value)
        • 5.2.3.1. Hospitals and Clinics
        • 5.2.3.2. Clinical Laboratories
        • 5.2.3.3. Home Care
      • 5.2.4. Global RSV Diagnostics by: Patient (Value)
        • 5.2.4.1. Infants
        • 5.2.4.2. Older Adults
      • 5.2.5. Global RSV Diagnostics by: RSV type (Value)
        • 5.2.5.1. Type A
        • 5.2.5.2. Type B
      • 5.2.6. Global RSV Diagnostics by: Method (Value)
        • 5.2.6.1. Rapid antigen detection tests (RADTs)
        • 5.2.6.2. Direct fluorescent antibody (DFA)
        • 5.2.6.3. Polymerase chain reaction (PCR) testing
        • 5.2.6.4. Molecular Diagnostics
        • 5.2.6.5. Enzyme-Linked Immunosorbent Assays
        • 5.2.6.6. Immunofluorescence Assays
        • 5.2.6.7. Chromatographic Immunoassays
        • 5.2.6.8. Optical Immunoassays
        • 5.2.6.9. Other Methods
      • 5.2.7. Global RSV Diagnostics Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global RSV Diagnostics (Volume)
      • 5.3.1. Global RSV Diagnostics by: Type (Volume)
        • 5.3.1.1. Kits and Assays
        • 5.3.1.2. Instruments
        • 5.3.1.3. Other Products
      • 5.3.2. Global RSV Diagnostics by: Application (Volume)
        • 5.3.2.1. Detection of RSV
        • 5.3.2.2. Prevention RSV
      • 5.3.3. Global RSV Diagnostics by: End-User (Volume)
        • 5.3.3.1. Hospitals and Clinics
        • 5.3.3.2. Clinical Laboratories
        • 5.3.3.3. Home Care
      • 5.3.4. Global RSV Diagnostics by: Patient (Volume)
        • 5.3.4.1. Infants
        • 5.3.4.2. Older Adults
      • 5.3.5. Global RSV Diagnostics by: RSV type (Volume)
        • 5.3.5.1. Type A
        • 5.3.5.2. Type B
      • 5.3.6. Global RSV Diagnostics by: Method (Volume)
        • 5.3.6.1. Rapid antigen detection tests (RADTs)
        • 5.3.6.2. Direct fluorescent antibody (DFA)
        • 5.3.6.3. Polymerase chain reaction (PCR) testing
        • 5.3.6.4. Molecular Diagnostics
        • 5.3.6.5. Enzyme-Linked Immunosorbent Assays
        • 5.3.6.6. Immunofluorescence Assays
        • 5.3.6.7. Chromatographic Immunoassays
        • 5.3.6.8. Optical Immunoassays
        • 5.3.6.9. Other Methods
      • 5.3.7. Global RSV Diagnostics Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global RSV Diagnostics (Price)
      • 5.4.1. Global RSV Diagnostics by: Type (Price)
  • 6. RSV Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton, Dickinson and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher Corporation (Cepheid Inc) (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sekisui diagnostics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vela Diagnostic (Singapore)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biomérieux (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Luminex (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biocartis (Belgium)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hologic (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global RSV Diagnostics Sale, by Type, Application, End-User, Patient, RSV type, Method and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global RSV Diagnostics (Value)
      • 7.2.1. Global RSV Diagnostics by: Type (Value)
        • 7.2.1.1. Kits and Assays
        • 7.2.1.2. Instruments
        • 7.2.1.3. Other Products
      • 7.2.2. Global RSV Diagnostics by: Application (Value)
        • 7.2.2.1. Detection of RSV
        • 7.2.2.2. Prevention RSV
      • 7.2.3. Global RSV Diagnostics by: End-User (Value)
        • 7.2.3.1. Hospitals and Clinics
        • 7.2.3.2. Clinical Laboratories
        • 7.2.3.3. Home Care
      • 7.2.4. Global RSV Diagnostics by: Patient (Value)
        • 7.2.4.1. Infants
        • 7.2.4.2. Older Adults
      • 7.2.5. Global RSV Diagnostics by: RSV type (Value)
        • 7.2.5.1. Type A
        • 7.2.5.2. Type B
      • 7.2.6. Global RSV Diagnostics by: Method (Value)
        • 7.2.6.1. Rapid antigen detection tests (RADTs)
        • 7.2.6.2. Direct fluorescent antibody (DFA)
        • 7.2.6.3. Polymerase chain reaction (PCR) testing
        • 7.2.6.4. Molecular Diagnostics
        • 7.2.6.5. Enzyme-Linked Immunosorbent Assays
        • 7.2.6.6. Immunofluorescence Assays
        • 7.2.6.7. Chromatographic Immunoassays
        • 7.2.6.8. Optical Immunoassays
        • 7.2.6.9. Other Methods
      • 7.2.7. Global RSV Diagnostics Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global RSV Diagnostics (Volume)
      • 7.3.1. Global RSV Diagnostics by: Type (Volume)
        • 7.3.1.1. Kits and Assays
        • 7.3.1.2. Instruments
        • 7.3.1.3. Other Products
      • 7.3.2. Global RSV Diagnostics by: Application (Volume)
        • 7.3.2.1. Detection of RSV
        • 7.3.2.2. Prevention RSV
      • 7.3.3. Global RSV Diagnostics by: End-User (Volume)
        • 7.3.3.1. Hospitals and Clinics
        • 7.3.3.2. Clinical Laboratories
        • 7.3.3.3. Home Care
      • 7.3.4. Global RSV Diagnostics by: Patient (Volume)
        • 7.3.4.1. Infants
        • 7.3.4.2. Older Adults
      • 7.3.5. Global RSV Diagnostics by: RSV type (Volume)
        • 7.3.5.1. Type A
        • 7.3.5.2. Type B
      • 7.3.6. Global RSV Diagnostics by: Method (Volume)
        • 7.3.6.1. Rapid antigen detection tests (RADTs)
        • 7.3.6.2. Direct fluorescent antibody (DFA)
        • 7.3.6.3. Polymerase chain reaction (PCR) testing
        • 7.3.6.4. Molecular Diagnostics
        • 7.3.6.5. Enzyme-Linked Immunosorbent Assays
        • 7.3.6.6. Immunofluorescence Assays
        • 7.3.6.7. Chromatographic Immunoassays
        • 7.3.6.8. Optical Immunoassays
        • 7.3.6.9. Other Methods
      • 7.3.7. Global RSV Diagnostics Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global RSV Diagnostics (Price)
      • 7.4.1. Global RSV Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. RSV Diagnostics: by Type(USD Million)
  • Table 2. RSV Diagnostics Kits and Assays , by Region USD Million (2013-2018)
  • Table 3. RSV Diagnostics Instruments , by Region USD Million (2013-2018)
  • Table 4. RSV Diagnostics Other Products , by Region USD Million (2013-2018)
  • Table 5. RSV Diagnostics: by Application(USD Million)
  • Table 6. RSV Diagnostics Detection of RSV , by Region USD Million (2013-2018)
  • Table 7. RSV Diagnostics Prevention RSV , by Region USD Million (2013-2018)
  • Table 8. RSV Diagnostics: by End-User(USD Million)
  • Table 9. RSV Diagnostics Hospitals and Clinics , by Region USD Million (2013-2018)
  • Table 10. RSV Diagnostics Clinical Laboratories , by Region USD Million (2013-2018)
  • Table 11. RSV Diagnostics Home Care , by Region USD Million (2013-2018)
  • Table 12. RSV Diagnostics: by Patient(USD Million)
  • Table 13. RSV Diagnostics Infants , by Region USD Million (2013-2018)
  • Table 14. RSV Diagnostics Older Adults , by Region USD Million (2013-2018)
  • Table 15. RSV Diagnostics: by RSV type(USD Million)
  • Table 16. RSV Diagnostics Type A , by Region USD Million (2013-2018)
  • Table 17. RSV Diagnostics Type B , by Region USD Million (2013-2018)
  • Table 18. RSV Diagnostics: by Method(USD Million)
  • Table 19. RSV Diagnostics Rapid antigen detection tests (RADTs) , by Region USD Million (2013-2018)
  • Table 20. RSV Diagnostics Direct fluorescent antibody (DFA) , by Region USD Million (2013-2018)
  • Table 21. RSV Diagnostics Polymerase chain reaction (PCR) testing , by Region USD Million (2013-2018)
  • Table 22. RSV Diagnostics Molecular Diagnostics , by Region USD Million (2013-2018)
  • Table 23. RSV Diagnostics Enzyme-Linked Immunosorbent Assays , by Region USD Million (2013-2018)
  • Table 24. RSV Diagnostics Immunofluorescence Assays , by Region USD Million (2013-2018)
  • Table 25. RSV Diagnostics Chromatographic Immunoassays , by Region USD Million (2013-2018)
  • Table 26. RSV Diagnostics Optical Immunoassays , by Region USD Million (2013-2018)
  • Table 27. RSV Diagnostics Other Methods , by Region USD Million (2013-2018)
  • Table 28. South America RSV Diagnostics, by Country USD Million (2013-2018)
  • Table 29. South America RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 30. South America RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 31. South America RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 32. South America RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 33. South America RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 34. South America RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 35. Brazil RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 36. Brazil RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 37. Brazil RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 38. Brazil RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 39. Brazil RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 40. Brazil RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 41. Argentina RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 42. Argentina RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 43. Argentina RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 44. Argentina RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 45. Argentina RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 46. Argentina RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 47. Rest of South America RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 48. Rest of South America RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 49. Rest of South America RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 50. Rest of South America RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 51. Rest of South America RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 52. Rest of South America RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 53. Asia Pacific RSV Diagnostics, by Country USD Million (2013-2018)
  • Table 54. Asia Pacific RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 55. Asia Pacific RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 56. Asia Pacific RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 57. Asia Pacific RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 58. Asia Pacific RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 59. Asia Pacific RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 60. China RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 61. China RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 62. China RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 63. China RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 64. China RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 65. China RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 66. Japan RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 67. Japan RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 68. Japan RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 69. Japan RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 70. Japan RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 71. Japan RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 72. India RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 73. India RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 74. India RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 75. India RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 76. India RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 77. India RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 78. South Korea RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 79. South Korea RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 80. South Korea RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 81. South Korea RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 82. South Korea RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 83. South Korea RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 84. Taiwan RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 85. Taiwan RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 86. Taiwan RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 87. Taiwan RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 88. Taiwan RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 89. Taiwan RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 90. Australia RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 91. Australia RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 92. Australia RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 93. Australia RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 94. Australia RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 95. Australia RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 96. Rest of Asia-Pacific RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 97. Rest of Asia-Pacific RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 98. Rest of Asia-Pacific RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 99. Rest of Asia-Pacific RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 100. Rest of Asia-Pacific RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 101. Rest of Asia-Pacific RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 102. Europe RSV Diagnostics, by Country USD Million (2013-2018)
  • Table 103. Europe RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 104. Europe RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 105. Europe RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 106. Europe RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 107. Europe RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 108. Europe RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 109. Germany RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 110. Germany RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 111. Germany RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 112. Germany RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 113. Germany RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 114. Germany RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 115. France RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 116. France RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 117. France RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 118. France RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 119. France RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 120. France RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 121. Italy RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 122. Italy RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 123. Italy RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 124. Italy RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 125. Italy RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 126. Italy RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 127. United Kingdom RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 128. United Kingdom RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 129. United Kingdom RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 130. United Kingdom RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 131. United Kingdom RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 132. United Kingdom RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 133. Netherlands RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 134. Netherlands RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 135. Netherlands RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 136. Netherlands RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 137. Netherlands RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 138. Netherlands RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 139. Rest of Europe RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 140. Rest of Europe RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 141. Rest of Europe RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 142. Rest of Europe RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 143. Rest of Europe RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 144. Rest of Europe RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 145. MEA RSV Diagnostics, by Country USD Million (2013-2018)
  • Table 146. MEA RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 147. MEA RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 148. MEA RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 149. MEA RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 150. MEA RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 151. MEA RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 152. Middle East RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 153. Middle East RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 154. Middle East RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 155. Middle East RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 156. Middle East RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 157. Middle East RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 158. Africa RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 159. Africa RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 160. Africa RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 161. Africa RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 162. Africa RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 163. Africa RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 164. North America RSV Diagnostics, by Country USD Million (2013-2018)
  • Table 165. North America RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 166. North America RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 167. North America RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 168. North America RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 169. North America RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 170. North America RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 171. United States RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 172. United States RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 173. United States RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 174. United States RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 175. United States RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 176. United States RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 177. Canada RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 178. Canada RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 179. Canada RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 180. Canada RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 181. Canada RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 182. Canada RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 183. Mexico RSV Diagnostics, by Type USD Million (2013-2018)
  • Table 184. Mexico RSV Diagnostics, by Application USD Million (2013-2018)
  • Table 185. Mexico RSV Diagnostics, by End-User USD Million (2013-2018)
  • Table 186. Mexico RSV Diagnostics, by Patient USD Million (2013-2018)
  • Table 187. Mexico RSV Diagnostics, by RSV type USD Million (2013-2018)
  • Table 188. Mexico RSV Diagnostics, by Method USD Million (2013-2018)
  • Table 189. RSV Diagnostics Sales: by Type(K Unit)
  • Table 190. RSV Diagnostics Sales Kits and Assays , by Region K Unit (2013-2018)
  • Table 191. RSV Diagnostics Sales Instruments , by Region K Unit (2013-2018)
  • Table 192. RSV Diagnostics Sales Other Products , by Region K Unit (2013-2018)
  • Table 193. RSV Diagnostics Sales: by Application(K Unit)
  • Table 194. RSV Diagnostics Sales Detection of RSV , by Region K Unit (2013-2018)
  • Table 195. RSV Diagnostics Sales Prevention RSV , by Region K Unit (2013-2018)
  • Table 196. RSV Diagnostics Sales: by End-User(K Unit)
  • Table 197. RSV Diagnostics Sales Hospitals and Clinics , by Region K Unit (2013-2018)
  • Table 198. RSV Diagnostics Sales Clinical Laboratories , by Region K Unit (2013-2018)
  • Table 199. RSV Diagnostics Sales Home Care , by Region K Unit (2013-2018)
  • Table 200. RSV Diagnostics Sales: by Patient(K Unit)
  • Table 201. RSV Diagnostics Sales Infants , by Region K Unit (2013-2018)
  • Table 202. RSV Diagnostics Sales Older Adults , by Region K Unit (2013-2018)
  • Table 203. RSV Diagnostics Sales: by RSV type(K Unit)
  • Table 204. RSV Diagnostics Sales Type A , by Region K Unit (2013-2018)
  • Table 205. RSV Diagnostics Sales Type B , by Region K Unit (2013-2018)
  • Table 206. RSV Diagnostics Sales: by Method(K Unit)
  • Table 207. RSV Diagnostics Sales Rapid antigen detection tests (RADTs) , by Region K Unit (2013-2018)
  • Table 208. RSV Diagnostics Sales Direct fluorescent antibody (DFA) , by Region K Unit (2013-2018)
  • Table 209. RSV Diagnostics Sales Polymerase chain reaction (PCR) testing , by Region K Unit (2013-2018)
  • Table 210. RSV Diagnostics Sales Molecular Diagnostics , by Region K Unit (2013-2018)
  • Table 211. RSV Diagnostics Sales Enzyme-Linked Immunosorbent Assays , by Region K Unit (2013-2018)
  • Table 212. RSV Diagnostics Sales Immunofluorescence Assays , by Region K Unit (2013-2018)
  • Table 213. RSV Diagnostics Sales Chromatographic Immunoassays , by Region K Unit (2013-2018)
  • Table 214. RSV Diagnostics Sales Optical Immunoassays , by Region K Unit (2013-2018)
  • Table 215. RSV Diagnostics Sales Other Methods , by Region K Unit (2013-2018)
  • Table 216. South America RSV Diagnostics Sales, by Country K Unit (2013-2018)
  • Table 217. South America RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 218. South America RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 219. South America RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 220. South America RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 221. South America RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 222. South America RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 223. Brazil RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 224. Brazil RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 225. Brazil RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 226. Brazil RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 227. Brazil RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 228. Brazil RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 229. Argentina RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 230. Argentina RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 231. Argentina RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 232. Argentina RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 233. Argentina RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 234. Argentina RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 235. Rest of South America RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 236. Rest of South America RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 237. Rest of South America RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 238. Rest of South America RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 239. Rest of South America RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 240. Rest of South America RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 241. Asia Pacific RSV Diagnostics Sales, by Country K Unit (2013-2018)
  • Table 242. Asia Pacific RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 243. Asia Pacific RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 244. Asia Pacific RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 245. Asia Pacific RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 246. Asia Pacific RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 247. Asia Pacific RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 248. China RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 249. China RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 250. China RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 251. China RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 252. China RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 253. China RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 254. Japan RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 255. Japan RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 256. Japan RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 257. Japan RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 258. Japan RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 259. Japan RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 260. India RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 261. India RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 262. India RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 263. India RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 264. India RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 265. India RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 266. South Korea RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 267. South Korea RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 268. South Korea RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 269. South Korea RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 270. South Korea RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 271. South Korea RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 272. Taiwan RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 273. Taiwan RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 274. Taiwan RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 275. Taiwan RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 276. Taiwan RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 277. Taiwan RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 278. Australia RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 279. Australia RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 280. Australia RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 281. Australia RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 282. Australia RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 283. Australia RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 284. Rest of Asia-Pacific RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 285. Rest of Asia-Pacific RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 286. Rest of Asia-Pacific RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 287. Rest of Asia-Pacific RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 288. Rest of Asia-Pacific RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 289. Rest of Asia-Pacific RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 290. Europe RSV Diagnostics Sales, by Country K Unit (2013-2018)
  • Table 291. Europe RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 292. Europe RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 293. Europe RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 294. Europe RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 295. Europe RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 296. Europe RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 297. Germany RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 298. Germany RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 299. Germany RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 300. Germany RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 301. Germany RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 302. Germany RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 303. France RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 304. France RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 305. France RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 306. France RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 307. France RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 308. France RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 309. Italy RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 310. Italy RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 311. Italy RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 312. Italy RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 313. Italy RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 314. Italy RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 315. United Kingdom RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 316. United Kingdom RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 317. United Kingdom RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 318. United Kingdom RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 319. United Kingdom RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 320. United Kingdom RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 321. Netherlands RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 322. Netherlands RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 323. Netherlands RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 324. Netherlands RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 325. Netherlands RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 326. Netherlands RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 327. Rest of Europe RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 328. Rest of Europe RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 329. Rest of Europe RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 330. Rest of Europe RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 331. Rest of Europe RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 332. Rest of Europe RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 333. MEA RSV Diagnostics Sales, by Country K Unit (2013-2018)
  • Table 334. MEA RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 335. MEA RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 336. MEA RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 337. MEA RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 338. MEA RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 339. MEA RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 340. Middle East RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 341. Middle East RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 342. Middle East RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 343. Middle East RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 344. Middle East RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 345. Middle East RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 346. Africa RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 347. Africa RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 348. Africa RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 349. Africa RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 350. Africa RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 351. Africa RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 352. North America RSV Diagnostics Sales, by Country K Unit (2013-2018)
  • Table 353. North America RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 354. North America RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 355. North America RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 356. North America RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 357. North America RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 358. North America RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 359. United States RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 360. United States RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 361. United States RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 362. United States RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 363. United States RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 364. United States RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 365. Canada RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 366. Canada RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 367. Canada RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 368. Canada RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 369. Canada RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 370. Canada RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 371. Mexico RSV Diagnostics Sales, by Type K Unit (2013-2018)
  • Table 372. Mexico RSV Diagnostics Sales, by Application K Unit (2013-2018)
  • Table 373. Mexico RSV Diagnostics Sales, by End-User K Unit (2013-2018)
  • Table 374. Mexico RSV Diagnostics Sales, by Patient K Unit (2013-2018)
  • Table 375. Mexico RSV Diagnostics Sales, by RSV type K Unit (2013-2018)
  • Table 376. Mexico RSV Diagnostics Sales, by Method K Unit (2013-2018)
  • Table 377. RSV Diagnostics: by Type(USD/Units)
  • Table 378. Company Basic Information, Sales Area and Its Competitors
  • Table 379. Company Basic Information, Sales Area and Its Competitors
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Company Basic Information, Sales Area and Its Competitors
  • Table 382. Company Basic Information, Sales Area and Its Competitors
  • Table 383. Company Basic Information, Sales Area and Its Competitors
  • Table 384. Company Basic Information, Sales Area and Its Competitors
  • Table 385. Company Basic Information, Sales Area and Its Competitors
  • Table 386. Company Basic Information, Sales Area and Its Competitors
  • Table 387. Company Basic Information, Sales Area and Its Competitors
  • Table 388. Company Basic Information, Sales Area and Its Competitors
  • Table 389. RSV Diagnostics: by Type(USD Million)
  • Table 390. RSV Diagnostics Kits and Assays , by Region USD Million (2019-2024)
  • Table 391. RSV Diagnostics Instruments , by Region USD Million (2019-2024)
  • Table 392. RSV Diagnostics Other Products , by Region USD Million (2019-2024)
  • Table 393. RSV Diagnostics: by Application(USD Million)
  • Table 394. RSV Diagnostics Detection of RSV , by Region USD Million (2019-2024)
  • Table 395. RSV Diagnostics Prevention RSV , by Region USD Million (2019-2024)
  • Table 396. RSV Diagnostics: by End-User(USD Million)
  • Table 397. RSV Diagnostics Hospitals and Clinics , by Region USD Million (2019-2024)
  • Table 398. RSV Diagnostics Clinical Laboratories , by Region USD Million (2019-2024)
  • Table 399. RSV Diagnostics Home Care , by Region USD Million (2019-2024)
  • Table 400. RSV Diagnostics: by Patient(USD Million)
  • Table 401. RSV Diagnostics Infants , by Region USD Million (2019-2024)
  • Table 402. RSV Diagnostics Older Adults , by Region USD Million (2019-2024)
  • Table 403. RSV Diagnostics: by RSV type(USD Million)
  • Table 404. RSV Diagnostics Type A , by Region USD Million (2019-2024)
  • Table 405. RSV Diagnostics Type B , by Region USD Million (2019-2024)
  • Table 406. RSV Diagnostics: by Method(USD Million)
  • Table 407. RSV Diagnostics Rapid antigen detection tests (RADTs) , by Region USD Million (2019-2024)
  • Table 408. RSV Diagnostics Direct fluorescent antibody (DFA) , by Region USD Million (2019-2024)
  • Table 409. RSV Diagnostics Polymerase chain reaction (PCR) testing , by Region USD Million (2019-2024)
  • Table 410. RSV Diagnostics Molecular Diagnostics , by Region USD Million (2019-2024)
  • Table 411. RSV Diagnostics Enzyme-Linked Immunosorbent Assays , by Region USD Million (2019-2024)
  • Table 412. RSV Diagnostics Immunofluorescence Assays , by Region USD Million (2019-2024)
  • Table 413. RSV Diagnostics Chromatographic Immunoassays , by Region USD Million (2019-2024)
  • Table 414. RSV Diagnostics Optical Immunoassays , by Region USD Million (2019-2024)
  • Table 415. RSV Diagnostics Other Methods , by Region USD Million (2019-2024)
  • Table 416. South America RSV Diagnostics, by Country USD Million (2019-2024)
  • Table 417. South America RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 418. South America RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 419. South America RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 420. South America RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 421. South America RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 422. South America RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 423. Brazil RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 424. Brazil RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 425. Brazil RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 426. Brazil RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 427. Brazil RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 428. Brazil RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 429. Argentina RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 430. Argentina RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 431. Argentina RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 432. Argentina RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 433. Argentina RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 434. Argentina RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 435. Rest of South America RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 436. Rest of South America RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 437. Rest of South America RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 438. Rest of South America RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 439. Rest of South America RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 440. Rest of South America RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 441. Asia Pacific RSV Diagnostics, by Country USD Million (2019-2024)
  • Table 442. Asia Pacific RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 443. Asia Pacific RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 444. Asia Pacific RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 445. Asia Pacific RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 446. Asia Pacific RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 447. Asia Pacific RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 448. China RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 449. China RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 450. China RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 451. China RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 452. China RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 453. China RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 454. Japan RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 455. Japan RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 456. Japan RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 457. Japan RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 458. Japan RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 459. Japan RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 460. India RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 461. India RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 462. India RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 463. India RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 464. India RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 465. India RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 466. South Korea RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 467. South Korea RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 468. South Korea RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 469. South Korea RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 470. South Korea RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 471. South Korea RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 472. Taiwan RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 473. Taiwan RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 474. Taiwan RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 475. Taiwan RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 476. Taiwan RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 477. Taiwan RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 478. Australia RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 479. Australia RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 480. Australia RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 481. Australia RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 482. Australia RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 483. Australia RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 484. Rest of Asia-Pacific RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 485. Rest of Asia-Pacific RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 486. Rest of Asia-Pacific RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 487. Rest of Asia-Pacific RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 488. Rest of Asia-Pacific RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 489. Rest of Asia-Pacific RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 490. Europe RSV Diagnostics, by Country USD Million (2019-2024)
  • Table 491. Europe RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 492. Europe RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 493. Europe RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 494. Europe RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 495. Europe RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 496. Europe RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 497. Germany RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 498. Germany RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 499. Germany RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 500. Germany RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 501. Germany RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 502. Germany RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 503. France RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 504. France RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 505. France RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 506. France RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 507. France RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 508. France RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 509. Italy RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 510. Italy RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 511. Italy RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 512. Italy RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 513. Italy RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 514. Italy RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 515. United Kingdom RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 516. United Kingdom RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 517. United Kingdom RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 518. United Kingdom RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 519. United Kingdom RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 520. United Kingdom RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 521. Netherlands RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 522. Netherlands RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 523. Netherlands RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 524. Netherlands RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 525. Netherlands RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 526. Netherlands RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 527. Rest of Europe RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 528. Rest of Europe RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 529. Rest of Europe RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 530. Rest of Europe RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 531. Rest of Europe RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 532. Rest of Europe RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 533. MEA RSV Diagnostics, by Country USD Million (2019-2024)
  • Table 534. MEA RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 535. MEA RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 536. MEA RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 537. MEA RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 538. MEA RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 539. MEA RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 540. Middle East RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 541. Middle East RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 542. Middle East RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 543. Middle East RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 544. Middle East RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 545. Middle East RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 546. Africa RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 547. Africa RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 548. Africa RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 549. Africa RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 550. Africa RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 551. Africa RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 552. North America RSV Diagnostics, by Country USD Million (2019-2024)
  • Table 553. North America RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 554. North America RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 555. North America RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 556. North America RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 557. North America RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 558. North America RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 559. United States RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 560. United States RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 561. United States RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 562. United States RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 563. United States RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 564. United States RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 565. Canada RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 566. Canada RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 567. Canada RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 568. Canada RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 569. Canada RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 570. Canada RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 571. Mexico RSV Diagnostics, by Type USD Million (2019-2024)
  • Table 572. Mexico RSV Diagnostics, by Application USD Million (2019-2024)
  • Table 573. Mexico RSV Diagnostics, by End-User USD Million (2019-2024)
  • Table 574. Mexico RSV Diagnostics, by Patient USD Million (2019-2024)
  • Table 575. Mexico RSV Diagnostics, by RSV type USD Million (2019-2024)
  • Table 576. Mexico RSV Diagnostics, by Method USD Million (2019-2024)
  • Table 577. RSV Diagnostics Sales: by Type(K Unit)
  • Table 578. RSV Diagnostics Sales Kits and Assays , by Region K Unit (2019-2024)
  • Table 579. RSV Diagnostics Sales Instruments , by Region K Unit (2019-2024)
  • Table 580. RSV Diagnostics Sales Other Products , by Region K Unit (2019-2024)
  • Table 581. RSV Diagnostics Sales: by Application(K Unit)
  • Table 582. RSV Diagnostics Sales Detection of RSV , by Region K Unit (2019-2024)
  • Table 583. RSV Diagnostics Sales Prevention RSV , by Region K Unit (2019-2024)
  • Table 584. RSV Diagnostics Sales: by End-User(K Unit)
  • Table 585. RSV Diagnostics Sales Hospitals and Clinics , by Region K Unit (2019-2024)
  • Table 586. RSV Diagnostics Sales Clinical Laboratories , by Region K Unit (2019-2024)
  • Table 587. RSV Diagnostics Sales Home Care , by Region K Unit (2019-2024)
  • Table 588. RSV Diagnostics Sales: by Patient(K Unit)
  • Table 589. RSV Diagnostics Sales Infants , by Region K Unit (2019-2024)
  • Table 590. RSV Diagnostics Sales Older Adults , by Region K Unit (2019-2024)
  • Table 591. RSV Diagnostics Sales: by RSV type(K Unit)
  • Table 592. RSV Diagnostics Sales Type A , by Region K Unit (2019-2024)
  • Table 593. RSV Diagnostics Sales Type B , by Region K Unit (2019-2024)
  • Table 594. RSV Diagnostics Sales: by Method(K Unit)
  • Table 595. RSV Diagnostics Sales Rapid antigen detection tests (RADTs) , by Region K Unit (2019-2024)
  • Table 596. RSV Diagnostics Sales Direct fluorescent antibody (DFA) , by Region K Unit (2019-2024)
  • Table 597. RSV Diagnostics Sales Polymerase chain reaction (PCR) testing , by Region K Unit (2019-2024)
  • Table 598. RSV Diagnostics Sales Molecular Diagnostics , by Region K Unit (2019-2024)
  • Table 599. RSV Diagnostics Sales Enzyme-Linked Immunosorbent Assays , by Region K Unit (2019-2024)
  • Table 600. RSV Diagnostics Sales Immunofluorescence Assays , by Region K Unit (2019-2024)
  • Table 601. RSV Diagnostics Sales Chromatographic Immunoassays , by Region K Unit (2019-2024)
  • Table 602. RSV Diagnostics Sales Optical Immunoassays , by Region K Unit (2019-2024)
  • Table 603. RSV Diagnostics Sales Other Methods , by Region K Unit (2019-2024)
  • Table 604. South America RSV Diagnostics Sales, by Country K Unit (2019-2024)
  • Table 605. South America RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 606. South America RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 607. South America RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 608. South America RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 609. South America RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 610. South America RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 611. Brazil RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 612. Brazil RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 613. Brazil RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 614. Brazil RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 615. Brazil RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 616. Brazil RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 617. Argentina RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 618. Argentina RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 619. Argentina RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 620. Argentina RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 621. Argentina RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 622. Argentina RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 623. Rest of South America RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 624. Rest of South America RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 625. Rest of South America RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 626. Rest of South America RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 627. Rest of South America RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 628. Rest of South America RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 629. Asia Pacific RSV Diagnostics Sales, by Country K Unit (2019-2024)
  • Table 630. Asia Pacific RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 631. Asia Pacific RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 632. Asia Pacific RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 633. Asia Pacific RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 634. Asia Pacific RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 635. Asia Pacific RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 636. China RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 637. China RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 638. China RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 639. China RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 640. China RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 641. China RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 642. Japan RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 643. Japan RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 644. Japan RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 645. Japan RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 646. Japan RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 647. Japan RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 648. India RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 649. India RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 650. India RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 651. India RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 652. India RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 653. India RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 654. South Korea RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 655. South Korea RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 656. South Korea RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 657. South Korea RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 658. South Korea RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 659. South Korea RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 660. Taiwan RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 661. Taiwan RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 662. Taiwan RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 663. Taiwan RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 664. Taiwan RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 665. Taiwan RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 666. Australia RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 667. Australia RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 668. Australia RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 669. Australia RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 670. Australia RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 671. Australia RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 672. Rest of Asia-Pacific RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 673. Rest of Asia-Pacific RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 674. Rest of Asia-Pacific RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 675. Rest of Asia-Pacific RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 676. Rest of Asia-Pacific RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 677. Rest of Asia-Pacific RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 678. Europe RSV Diagnostics Sales, by Country K Unit (2019-2024)
  • Table 679. Europe RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 680. Europe RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 681. Europe RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 682. Europe RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 683. Europe RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 684. Europe RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 685. Germany RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 686. Germany RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 687. Germany RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 688. Germany RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 689. Germany RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 690. Germany RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 691. France RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 692. France RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 693. France RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 694. France RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 695. France RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 696. France RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 697. Italy RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 698. Italy RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 699. Italy RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 700. Italy RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 701. Italy RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 702. Italy RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 703. United Kingdom RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 704. United Kingdom RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 705. United Kingdom RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 706. United Kingdom RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 707. United Kingdom RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 708. United Kingdom RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 709. Netherlands RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 710. Netherlands RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 711. Netherlands RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 712. Netherlands RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 713. Netherlands RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 714. Netherlands RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 715. Rest of Europe RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 716. Rest of Europe RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 717. Rest of Europe RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 718. Rest of Europe RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 719. Rest of Europe RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 720. Rest of Europe RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 721. MEA RSV Diagnostics Sales, by Country K Unit (2019-2024)
  • Table 722. MEA RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 723. MEA RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 724. MEA RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 725. MEA RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 726. MEA RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 727. MEA RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 728. Middle East RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 729. Middle East RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 730. Middle East RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 731. Middle East RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 732. Middle East RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 733. Middle East RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 734. Africa RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 735. Africa RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 736. Africa RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 737. Africa RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 738. Africa RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 739. Africa RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 740. North America RSV Diagnostics Sales, by Country K Unit (2019-2024)
  • Table 741. North America RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 742. North America RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 743. North America RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 744. North America RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 745. North America RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 746. North America RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 747. United States RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 748. United States RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 749. United States RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 750. United States RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 751. United States RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 752. United States RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 753. Canada RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 754. Canada RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 755. Canada RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 756. Canada RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 757. Canada RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 758. Canada RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 759. Mexico RSV Diagnostics Sales, by Type K Unit (2019-2024)
  • Table 760. Mexico RSV Diagnostics Sales, by Application K Unit (2019-2024)
  • Table 761. Mexico RSV Diagnostics Sales, by End-User K Unit (2019-2024)
  • Table 762. Mexico RSV Diagnostics Sales, by Patient K Unit (2019-2024)
  • Table 763. Mexico RSV Diagnostics Sales, by RSV type K Unit (2019-2024)
  • Table 764. Mexico RSV Diagnostics Sales, by Method K Unit (2019-2024)
  • Table 765. RSV Diagnostics: by Type(USD/Units)
  • Table 766. Research Programs/Design for This Report
  • Table 767. Key Data Information from Secondary Sources
  • Table 768. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global RSV Diagnostics: by Type USD Million (2013-2018)
  • Figure 5. Global RSV Diagnostics: by Application USD Million (2013-2018)
  • Figure 6. Global RSV Diagnostics: by End-User USD Million (2013-2018)
  • Figure 7. Global RSV Diagnostics: by Patient USD Million (2013-2018)
  • Figure 8. Global RSV Diagnostics: by RSV type USD Million (2013-2018)
  • Figure 9. Global RSV Diagnostics: by Method USD Million (2013-2018)
  • Figure 10. South America RSV Diagnostics Share (%), by Country
  • Figure 11. Asia Pacific RSV Diagnostics Share (%), by Country
  • Figure 12. Europe RSV Diagnostics Share (%), by Country
  • Figure 13. MEA RSV Diagnostics Share (%), by Country
  • Figure 14. North America RSV Diagnostics Share (%), by Country
  • Figure 15. Global RSV Diagnostics: by Type K Unit (2013-2018)
  • Figure 16. Global RSV Diagnostics: by Application K Unit (2013-2018)
  • Figure 17. Global RSV Diagnostics: by End-User K Unit (2013-2018)
  • Figure 18. Global RSV Diagnostics: by Patient K Unit (2013-2018)
  • Figure 19. Global RSV Diagnostics: by RSV type K Unit (2013-2018)
  • Figure 20. Global RSV Diagnostics: by Method K Unit (2013-2018)
  • Figure 21. South America RSV Diagnostics Share (%), by Country
  • Figure 22. Asia Pacific RSV Diagnostics Share (%), by Country
  • Figure 23. Europe RSV Diagnostics Share (%), by Country
  • Figure 24. MEA RSV Diagnostics Share (%), by Country
  • Figure 25. North America RSV Diagnostics Share (%), by Country
  • Figure 26. Global RSV Diagnostics: by Type USD/Units (2013-2018)
  • Figure 27. Global RSV Diagnostics share by Players 2018 (%)
  • Figure 28. Global RSV Diagnostics share by Players (Top 3) 2018(%)
  • Figure 29. Global RSV Diagnostics share by Players (Top 5) 2018(%)
  • Figure 30. BCG Matrix for key Companies
  • Figure 31. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott (United States) Revenue: by Geography 2018
  • Figure 33. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Becton, Dickinson and Company (United States) Revenue: by Geography 2018
  • Figure 35. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Roche (Switzerland) Revenue: by Geography 2018
  • Figure 37. Danaher Corporation (Cepheid Inc) (United States) Revenue, Net Income and Gross profit
  • Figure 38. Danaher Corporation (Cepheid Inc) (United States) Revenue: by Geography 2018
  • Figure 39. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 40. Thermo Fisher Scientific (United States) Revenue: by Geography 2018
  • Figure 41. Sekisui diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 42. Sekisui diagnostics (United States) Revenue: by Geography 2018
  • Figure 43. Vela Diagnostic (Singapore) Revenue, Net Income and Gross profit
  • Figure 44. Vela Diagnostic (Singapore) Revenue: by Geography 2018
  • Figure 45. Biomérieux (France) Revenue, Net Income and Gross profit
  • Figure 46. Biomérieux (France) Revenue: by Geography 2018
  • Figure 47. Luminex (United States) Revenue, Net Income and Gross profit
  • Figure 48. Luminex (United States) Revenue: by Geography 2018
  • Figure 49. Biocartis (Belgium) Revenue, Net Income and Gross profit
  • Figure 50. Biocartis (Belgium) Revenue: by Geography 2018
  • Figure 51. Hologic (United States) Revenue, Net Income and Gross profit
  • Figure 52. Hologic (United States) Revenue: by Geography 2018
  • Figure 53. Global RSV Diagnostics: by Type USD Million (2019-2024)
  • Figure 54. Global RSV Diagnostics: by Application USD Million (2019-2024)
  • Figure 55. Global RSV Diagnostics: by End-User USD Million (2019-2024)
  • Figure 56. Global RSV Diagnostics: by Patient USD Million (2019-2024)
  • Figure 57. Global RSV Diagnostics: by RSV type USD Million (2019-2024)
  • Figure 58. Global RSV Diagnostics: by Method USD Million (2019-2024)
  • Figure 59. South America RSV Diagnostics Share (%), by Country
  • Figure 60. Asia Pacific RSV Diagnostics Share (%), by Country
  • Figure 61. Europe RSV Diagnostics Share (%), by Country
  • Figure 62. MEA RSV Diagnostics Share (%), by Country
  • Figure 63. North America RSV Diagnostics Share (%), by Country
  • Figure 64. Global RSV Diagnostics: by Type K Unit (2019-2024)
  • Figure 65. Global RSV Diagnostics: by Application K Unit (2019-2024)
  • Figure 66. Global RSV Diagnostics: by End-User K Unit (2019-2024)
  • Figure 67. Global RSV Diagnostics: by Patient K Unit (2019-2024)
  • Figure 68. Global RSV Diagnostics: by RSV type K Unit (2019-2024)
  • Figure 69. Global RSV Diagnostics: by Method K Unit (2019-2024)
  • Figure 70. South America RSV Diagnostics Share (%), by Country
  • Figure 71. Asia Pacific RSV Diagnostics Share (%), by Country
  • Figure 72. Europe RSV Diagnostics Share (%), by Country
  • Figure 73. MEA RSV Diagnostics Share (%), by Country
  • Figure 74. North America RSV Diagnostics Share (%), by Country
  • Figure 75. Global RSV Diagnostics: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Becton, Dickinson and Company (United States)
  • Roche (Switzerland)
  • Danaher Corporation (Cepheid Inc) (United States)
  • Thermo Fisher Scientific (United States)
  • Sekisui diagnostics (United States)
  • Vela Diagnostic (Singapore)
  • Biomérieux (France)
  • Luminex (United States)
  • Biocartis (Belgium)
  • Hologic (United States)
Select User Access Type

Key Highlights of Report


Feb 2020 213 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global RSV Diagnostics Report?